- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06350695
The ROle of Compression StocKings in Heart Failure Patients (ROCK-HF)
Study Overview
Status
Detailed Description
Introduction Heart failure (HF) affects 6.2 million patients in the United States and was responsible of 13.4% of deaths in 2018 costing about 30.7 billion USD in 2012, and about 80% of all the patients with HF are >65 years old. Clinical manifestations include shortness of breath and peripheral edema. Diuretics are indicated to treat edema in patients with HF, however, its use is limited in patients with compromised kidney function. Peripheral edema is associated with pain, heavy legs, limited mobility, and poor quality of life, increasing the risk of cellulitis, and wounds. Heart failure was identified in up to 44% of patients with venous ulcers. The chronic use of compression stockings in HF patients has potential benefits such as a better control of the edema, decreasing the need for diuretics, improving mobility, prevention of progression of venous disease, and prevention of venous ulcers. To date, no major HF guidelines recommend in favor or against compression stockings in HF patients.
Previous studies in patients with HF who had a pulmonary artery catheter in place, showed that compression of the lower extremities increases the right atrial pressure. However, it was a short intervention, and there was no evidence of clinical deterioration or worsening symptoms of HF. A retrospective review from a wound center showed that the use of compression therapy in HF patient was not associated with an increase in death, hospitalizations, or use of diuretics.
Hypothesis: The hypothesis is the use of compression stockings would prevent developing or worsening venous disease (venous reflux, and venous ulcers), improving the edema of the lower extremities, mobility and quality of life in HF patients without increasing the risk of HF deterioration, hospitalization, or death. To obtain preliminary information, this study proposes to randomize 30 patients with HF (New York Heart Association class II-III, stage A, B or C) on maximum medical therapy to 3 months of compression stockings 20-30 mmHg knee high (High compression group, n=15) vs. regular stocking with ≤10 mmHg of compression (Low compression group, n=15).
Aim 1. To determine whether the use of graduated 20-30 mmHg compression stockings are associated with clinical deterioration or increase is hospitalization or death in patients with HF. Patients will be evaluated at baseline, in a week after enrollment (telemedicine), and at three months. The New York Heart Association (NYHA) clinical classification, the Kansas City Cardiomyopathy Questionnaire (KCCQ), levels of brain natriuretic peptide, serum creatinine, documentation of diuretic therapy, body weight, visits to the Emergency Department, hospitalizations and deaths will be obtained on the baseline and 3-month visit. The change in NYHA clinical classification, KCCQ, body weight, diuretic dosage and any adverse events will be compared at 3 months.
AIM 2a. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with prevention of developing or worsening venous reflux. The presence of venous reflux will be documented with a venous duplex of the lower extremities looking for reflux and obstruction. The difference in time (3-month - baseline) of venous valve closure in milliseconds in bilateral common iliac, common femoral, femoral, popliteal veins, saphenous-femoral junction, great saphenous and small saphenous veins will be documented and compared between high compression and low compression stocking groups.
AIM 2b. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with prevention of developing or worsening clinical signs of venous insufficiency (C class of CEAP C1-C6). A brief physical exam of the lower extremities will be performed to obtain the C class for the CEAP classification for venous disease at baseline and 3 months. The C score will be compared between high compression and low compression stocking groups.
Aim 3. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with improvement of mobility and quality of life in heart failure patients. The quality of life will be documented using the VEINS QoL and SF-36 questionnaires; and the mobility will be assessed using the Short Physical Performance Battery test (SPPB). Patients will be evaluated at baseline and at 3-months visits. The difference in scores (3-month - baseline) will be compared between high compression and low compression stocking groups.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rafael S Cires-Drouet, MD
- Phone Number: 410-328-5842
- Email: rcires@som.umaryland.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland
-
Principal Investigator:
- Rafael S Cires-Drouet, MD
-
Contact:
- Rydica Newton, Research Coordinator
- Phone Number: 410-706-3941
- Email: RNewton@som.umaryland.edu
-
Contact:
- Kim Nordstrom
- Email: knordstrom@som.umaryland.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years and older
- Diagnosis of Heart failure NYHA II-III Class A, B, or C.
- Pitting edema of the lower extremities
Exclusion Criteria:
- Peripheral arterial disease with ABI of 0.5 or less
- Severe decompensated heart failure NYHA IV
- Unstable acute coronary syndrome
- Severe valvular stenosis or regurgitation
- Hypertrophic obstructive cardiomyopathy
- Unstable arrhythmia without a defibrillator
- On renal replacement therapy, hemodialysis of peritoneal dialysis
- Morbid obesity with a BMI > 40
- Pregnancy
- Lymphedema or Lipoedema
- Unable to put the compression stockings on by him/ herself or a person to do it for the patient
- Septic phlebitis, acute bacterial, viral or allergic inflammation of the legs
- Expectancy of life less than 6 months
- Unable to read or understand English language
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: low grade compression stocking arm
Patients will be assigned to receive 2 pairs of low grade compression stockings (10-15 mmHg), that they will be wearing at least 8 hours a day 5 days a week.
|
Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week
|
Experimental: high grade compression stocking arm
Patients will be assigned to receive 2 pairs of high grade compression stockings (20-30 mmHg), that they will be wearing at least 8 hours a day 5 days a week.
|
Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events.
Time Frame: 3 months
|
The number of adverse events (deaths and hospitalizations) will be recorded and compared between each group.
|
3 months
|
Change in symptoms of heart failure.
Time Frame: 3 months
|
This outcome measures the changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from each group.
KCCQ scores are from 0-100.
The higher the score the better the patient is.
|
3 months
|
Change in kidney function.
Time Frame: 3 months
|
This outcome measures the change in BUN and creatinine from each group.
BUN and creatinine will be measured in mg/dl.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in venous reflux.
Time Frame: 3 months
|
This outcome measures the change in valve closure time (VCT) in milliseconds between the two groups.
|
3 months
|
Change in C Class from the CEAP classification for venous insufficiency.
Time Frame: 3 months
|
C class range from C0 to C6 and describe the clinical signs of venous insufficiency.
This outcome will measure the difference of C class between both groups.
|
3 months
|
Mobility of the patient
Time Frame: 3 months
|
To measure mobility the Short Physical Performance Battery (SPPB) test is used.
The test scores from 0-12.
This outcome compares change in SPPB scores between both groups.
|
3 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00103478
- 1R21AG080424-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Insufficiency
-
Value Outcomes Ltd.Alfasigma S.p.A.RecruitingChronic Venous Disease | Chronic Insufficiency VenousCzechia
-
State Budgetary Healthcare Institution, National...CompletedEndothelial Dysfunction | Venous Insufficiency of Leg | Venous Insufficiency (Chronic)(Peripheral)Russian Federation
-
GCS Ramsay Santé pour l'Enseignement et la RechercheVivactis M2ResearchRecruitingSuperficial Venous InsufficiencyFrance
-
C. R. BardEnrolling by invitation
-
Medtronic EndovascularCompletedVenous Insufficiency of LegUnited Kingdom, Denmark, Germany, Netherlands
-
Hancock Jaffe Laboratiores, IncSyntactx; AXIOM Real Time MetricsRecruitingDeep Venous Insufficiency (Diagnosis)United States
-
Medtronic EndovascularCompleted
-
TheraclionRecruitingChronic Venous InsufficiencyUnited States, Austria, Czechia
-
Technical University of LisbonFundação para a Ciência e a Tecnologia; Escola Superior de Saúde Dr. Lopes...CompletedChronic Venous InsufficiencyPortugal
-
Tong ZhuNot yet recruitingDeep Vein Thrombosis | Deep Venous Insufficiency
Clinical Trials on low grade compression stockings (10-15 mmHg)
-
Karadeniz Technical UniversityUnknown
-
Tehran Heart CenterIsfahan University of Medical Sciences; Tehran Arrhythmia Center; Rajaie Cardiovascular... and other collaboratorsRecruitingSyncope, VasovagalIran, Islamic Republic of
-
University of RostockCompletedKnee Pain SwellingGermany
-
Jesper KjaergaardOdense University HospitalCompletedBlood Pressure | Out-of-Hospital Cardiac Arrest | Hemodynamic InstabilityDenmark
-
Loyola UniversityUnknownPancreas CancerUnited States
-
University of Southern DenmarkRecruitingIntensive Care Unit | Out-Of-Hospital Cardiac Arrest | Mechanical Ventilation | Resuscitation | Oxygen Therapy | Hypertension, Pulmonary ArterialDenmark
-
Pirogov Russian National Research Medical UniversityCompletedDeep Vein Thrombosis | Postthrombotic SyndromeRussian Federation
-
Botanix PharmaceuticalsCompletedHyperhidrosisUnited States
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompleted
-
Botanix PharmaceuticalsCompletedHyperhidrosisUnited States